Insurance data from Purple Lab and GLP-1 Newsroom highlights stark regional differences in the prescription rates of GLP-1 medications like Ozempic and Mounjaro. Obesity-heavy states are seeing triple the prescription rates compared to other regions. These medications are increasingly being used not just for diabetes but also for obesity, vascular disease prevention, and addiction management. President Trump’s potential price reductions for these drugs could further boost their usage.
The data from the Trust for America’s Health underscores the growing obesity crisis, with 19 states now having obesity rates of at least 35%. While states in the South and Midwest show the highest prescription rates for GLP-1 drugs, coastal and Western states have the lowest usage. This data underscores the urgent need for policies that support healthy living and accessibility to effective treatments.